BioSpace News Archive

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 13, 2020 at 8:30 a.m. ET to report financial results

Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that the Cocrystal management team, will present at the H.C. Wainwright 6th Annual Israel Conference on Thursday, November 12, 2020 at 12:00 PM EST.

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data from the Phase 2 Zella 201 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, will be presented at the 62nd American Society of Hematology Annual Meeting,

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 10 new employees.

BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the execution of a commercial partnership agreement with Scott Specialties Inc (SS http://scottspecialties.com/) to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy® (DJO www.djoglobal.com) Advantage product line.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease (aGVHD)

The platelet function test market may garner considerable growth during the assessment period of 2020-2030.

Jubilant Pharma Ltd. and Aavis Pharmaceuticals Inc. announce the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil 200 mg in the U.S. market.

Funds support clinical development of potent antibodies for the immunotherapy of COVID-19 and for BK virus infection in kidney transplant patients